Stanford Medicine researchers have developed a groundbreaking universal vaccine delivered as a nasal spray that protects against multiple respiratory viruses, bacteria, and allergens. In mouse studies, the vaccine provided broad protection for several months against SARS-CoV-2, Staphylococcus aureus, Acinetobacter baumannii, and house dust mites. The vaccine works by mimicking immune cell communication signals rather than targeting specific pathogens.

Unlike traditional vaccines that rely on antigen specificity, this approach integrates both innate and adaptive immunity through a feedback loop. The innate immune system, typically short-lived, is sustained by signals from recruited T cells, creating prolonged protection. Researchers were surprised by the vaccine's effectiveness across such a diverse range of respiratory threats, calling it a "double whammy" that both reduces viral loads by 700-fold and enables rapid adaptive responses.

The vaccine, currently known as GLA-3M-052-LS+OVA, contains a harmless antigen called ovalbumin that helps maintain the immune response. If successful in human trials, this could replace multiple annual jabs for seasonal infections and provide protection against emerging pandemic viruses. The research team plans to begin Phase I safety trials next.